Endocrine Abstracts

Background: Ergot-derived dopamine agonist therapy (EDDAT) is associated with cardiac valvulopathy in Parkinson’s disease. The risk to patients with prolactinomas is uncertain. The EMEA/MRHA and BSE recently issued guidelines for surveillance echocardiography (ECHO) of patients receiving treatment with EDDAT. Our policy is to arrange opportunistic ECHO screening at first clinic visit guidelines.Objective: We investigated the uptake and findings of e...